Immuno-Biological Laboratories Co (TSE:4570) Total Current Liabilities: 円276 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4570 Immuno-Biological Laboratories Co Ltd TSE:4570
58 GF Score
Price 円980.00
GF Value 円579.30
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Immuno-Biological Laboratories Co Total Current Liabilities?

Immuno-Biological Laboratories Co TSE:4570 -4.76% 58 Total Current Liabilities is 円276 Mil as of Mar. 2026. GuruFocus rates TSE:4570 with a GF Score™ of 58/100 and a GF Value™ of 円579.30 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Immuno-Biological Laboratories Co's total current liabilities for the quarter that ended in Mar. 2026 was 円276

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Immuno-Biological Laboratories Co Total Current Liabilities Related Terms

Immuno-Biological Laboratories Co Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Immuno-Biological Laboratories Co's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immuno-Biological Laboratories Co Total Current Liabilities Chart

Immuno-Biological Laboratories Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 228.08 252.01 257.82 281.34 276.19

Immuno-Biological Laboratories Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 257.82 262.30 281.34 269.86 276.19
TSE:4570
58GF Score
Immuno-Biological Laboratories Co Ltd TSE:4570
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immuno-Biological Laboratories Co Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Immuno-Biological Laboratories Co's Total Current Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=7.612+158.417
+Other Current Liabilities+Current Deferred Liabilities
=110.165+0
=276

Immuno-Biological Laboratories Co's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=7.612+158.417
+Other Current Liabilities+Current Deferred Liabilities
=110.165+0
=276

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of 円276 Mil mean?
Immuno-Biological Laboratories Co (TSE:4570) has a Total Current Liabilities of 円276 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Immuno-Biological Laboratories Co and its competitors.
Is Immuno-Biological Laboratories Co's Total Current Liabilities too high?
Immuno-Biological Laboratories Co's current Total Current Liabilities is 円276 Mil. Overall, Immuno-Biological Laboratories Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immuno-Biological Laboratories Co's Total Current Liabilities compare to VRTX and REGN?
Immuno-Biological Laboratories Co's Total Current Liabilities of 円276 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Immuno-Biological Laboratories Co and its competitors. Immuno-Biological Laboratories Co's current Total Current Liabilities is 円276 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuno-Biological Laboratories Co stock overvalued right now?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co (TSE:4570) is currently considered Significantly Overvalued. The stock's GF Value™ is 円579.30, compared to a current price of 円980.00 — trading 69.2% above its estimated fair value. The current Total Current Liabilities is 円276 Mil. Immuno-Biological Laboratories Co's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Immuno-Biological Laboratories Co (TSE:4570), the current Total Current Liabilities is 円276 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immuno-Biological Laboratories Co (TSE:4570) Overvalued in 2026?

Based on GuruFocus' analysis, Immuno-Biological Laboratories Co stock appears to be overvalued. The current stock price of 円980.00 is trading 69.2% above its estimated GF Value™ of 円579.30. GuruFocus considers Immuno-Biological Laboratories Co to be Significantly Overvalued.

Key valuation signals for TSE:4570:

  • Total Current Liabilities: 円276 Mil
  • GF Value™: 円579.30 vs. price of 円980.00 (69.2% above fair value)
  • GF Score™: 58/100 with 2 warning signs

No single metric tells the full story. See the TSE:4570 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immuno-Biological Laboratories Co Business Description

Address 1091-1 Naka Aza-Higashida, Gunma, Fujioka, JPN, 375-0005
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.
58GF Score

Get the complete analysis for TSE:4570

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円980.00
Price
円579.30
GF Value